Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low‐dose bacillus Calmette‐Guérin for superficial bladder cancer recurrence
- 28 March 2003
- journal article
- Published by Wiley in International Journal of Urology
- Vol. 10 (4), 183-189
- https://doi.org/10.1046/j.0919-8172.2003.00607.x
Abstract
Intravesical instillation of bacillus Calmette-Guérin (BCG) is the most efficient strategy for prophylaxis of superficial bladder cancer recurrence. Adverse effects of BCG are major obstacles, but the reduction of BCG dose could minimize these effects. The efficacy and adverse effects of half-dose (40 mg) BCG, Tokyo 172 strain, were prospectively evaluated. A total of 93 patients with superficial bladder cancer (pTa or pT1) were sequentially assigned to receive either 40 or 80 mg of BCG after transurethral resection. BCG was administered weekly for 6 weeks postoperatively. Eighty patients observed longer than 12 months after BCG therapy (41, 40 mg group; 39, 80 mg group) were analyzed. BCG therapy course was completed in 71 patients. Tumor recurrence was recognized in 11 of 40 patients in the 40 mg group and in 5 of 31 patients in the 80 mg group. There was no significant difference in tumor recurrence rate between the two groups (P = 0.547). BCG therapy was withdrawn in 1 patient in the 40 mg group and in 8 patients in the 80 mg-group because of BCG-related adverse effects. The morbidity of BCG-related toxicity was significantly higher in the 80 mg group. Half-dose of BCG Tokyo 172 strain had a similar efficacy and its toxicity was significantly lower compared to the standard dose. Thus, half-dose of this strain might be suitable, at least for initial BCG therapy, for the prophylaxis of bladder cancer recurrence. Further study would be necessary to clarify the efficacy of low-dose instillation in high-risk patients.Keywords
This publication has 25 references indexed in Scilit:
- Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, 2002
- Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, 2002
- THE ABLATIVE EFFECT OF QUARTER DOSE BACILLUS CALMETTE-GUERIN ON A PAPILLARY MARKER LESION OF THE BLADDERJournal of Urology, 2001
- MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER:Journal of Urology, 2000
- RECURRENCE, PROGRESSION AND SUCCESS IN STAGE TA GRADE 3 BLADDER TUMORS TREATED WITH LOW DOSE BACILLUS CALMETTE-GUERIN INSTILLATIONSJournal of Urology, 2000
- CORRELATION BETWEEN p53 OVER EXPRESSION AND RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY IN A HIGH RISK SELECT POPULATION OF PATIENTS WITH T1G3 BLADDER CANCERJournal of Urology, 1998
- Recurrence of Primary Superficial Bladder Cancer Treated with Prophylactic Intravesical Tokyo 172 Bacillus Calmette‐Guerin: A Long‐Term Follow‐upInternational Journal of Urology, 1997
- Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer TherapyJournal of Urology, 1996
- Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer TherapyJournal of Urology, 1996
- Intravesical BCG Treatment for Superficial Bladder Cancer: Long‐term Results using Two Different Strains of BCGBJU International, 1992